ストックスクリーナーアプリを入手
45.95
2.45%
1.10
アフターアワーズ：
45.88
-0.07
-0.15%
前日終値:
$44.85
開ける：
$45.22
24時間の取引高:
932.28K
Relative Volume:
1.15
時価総額：
$2.36B
収益：
$1.28B
当期純損益:
$-222.15M
株価収益率:
-11.23
EPS:
-4.09
ネットキャッシュフロー:
$145.52M
1週間 パフォーマンス:
+6.24%
1か月 パフォーマンス:
+30.69%
6か月 パフォーマンス:
-7.56%
1年 パフォーマンス:
-12.97%
1日の値動き範囲:
$45.22
$46.11
1週間の範囲:
$42.79
$46.11
52週間の値動き範囲:
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
LIVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
45.95 | 2.36B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-02-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | 開始されました | Goldman | Buy |
| 2024-09-17 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | 繰り返されました | Needham | Buy |
| 2024-02-20 | アップグレード | Mizuho | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Hold |
| 2023-07-19 | 開始されました | Robert W. Baird | Neutral |
| 2023-04-14 | 開始されました | Mizuho | Neutral |
| 2022-12-21 | 開始されました | Barclays | Equal Weight |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-02-24 | アップグレード | UBS | Neutral → Buy |
| 2021-12-03 | 開始されました | Goldman | Buy |
| 2021-08-20 | 繰り返されました | Needham | Buy |
| 2021-07-20 | アップグレード | Needham | Hold → Buy |
| 2021-03-03 | ダウングレード | Berenberg | Buy → Hold |
| 2021-01-05 | ダウングレード | Needham | Buy → Hold |
| 2020-09-02 | 開始されました | Robert W. Baird | Outperform |
| 2020-06-26 | 繰り返されました | Needham | Buy |
| 2019-10-30 | 繰り返されました | Needham | Buy |
| 2019-02-28 | 繰り返されました | Needham | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-08-02 | 繰り返されました | Needham | Buy |
| 2018-06-08 | 開始されました | Stifel | Buy |
| 2018-05-31 | 繰り返されました | Needham | Buy |
| 2018-02-28 | 繰り返されました | Needham | Buy |
すべてを表示
Livanova Plc (LIVN) 最新ニュース
LivaNova completes epilepsy treatment study of VNS Therapy - Medical Device Network
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - BioSpace
LivaNova at Jefferies Conference: Strategic Growth and Challenges - Investing.com
LivaNova at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Artificial Heart Lung Machines Market Projected to Witness - openPR.com
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy | LIVN Stock News - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy By Investing.com - Investing.com UK
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy | LIVN Stock - GuruFocus
LivaNova plc (LIVN) completes CORE-VNS study - StreetInsider
VNS therapy shows sustained seizure reduction in study - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - The Joplin Globe
VNS therapy shows sustained seizure reduction in study By Investing.com - Investing.com UK
LivaNova (LIVN) Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - StreetInsider
LivaNova seeks Medicare coverage reconsideration for VNS Therapy By Investing.com - Investing.com South Africa
LivaNova wants CMS to reconsider neuromod for treating depression - MassDevice
Bioelectronic Medicine Market Research Report 2025 Featuring Key PlayersMedtronic, Abbott, Boston Scientific, Cochlear, LivaNova, Soterix Medical, Bioinduction, GiMer Medical, CEFALY, BioControl - GlobeNewswire
LivaNova Seeks Reconsideration of National Medicare Coverage for VNS Depression Treatment - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Me - GuruFocus
LivaNova (LIVN) Seeks Expanded Medicare Coverage for VNS Therapy | LIVN Stock News - GuruFocus
LivaNova seeks Medicare coverage reconsideration for VNS Therapy - Investing.com India
LivaNova (LIVN) Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - StreetInsider
LivaNova Announces 12-month Data from OSPREY Study - Medical Product Outsourcing
Vagus Nerve Stimulation (VNS) Market Poised for Breakthrough Growth: From $488.5M in 2022 to $836.1M by 2032 - openPR.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Analysts - Defense World
Electroceuticals Market Generated Opportunities, Future - openPR.com
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles By Investing.com - Investing.com India
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles - Investing.com Australia
LivaNova's SWOT analysis: medical device firm's stock faces growth hurdles - Investing.com
(LIVN) Technical Data - news.stocktradersdaily.com
LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Deutsche Bank AG - Defense World
LivaNova faces $360M liability after court ruling By Investing.com - Investing.com South Africa
LivaNova faces $360M liability after court ruling - Investing.com India
LivaNova (NASDAQ:LIVN) Raised to Outperform at Wolfe Research - Defense World
LivaNova Faces Legal Dispute Over Environmental Liabilities - TipRanks
Wolfe Research Upgrades LivaNova (LIVN) - Nasdaq
LivaNova (LIVN) Receives Upgrade to "Outperform" by Wolfe Research | LIVN Stock News - GuruFocus
Wolfe Research lifts Livanova stock rating, sets $60 target By Investing.com - Investing.com Nigeria
LivaNova (LIVN) Upgraded by Wolfe Research with a Positive Outlo - GuruFocus
LivaNova (LIVN) Upgraded by Wolfe Research with a Positive Outlook | LIVN Stock News - GuruFocus
LivaNova (LIVN) Receives Upgrade to "Outperform" by Wolfe Resear - GuruFocus
Bank of America Corp DE Sells 94,006 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
LivaNova PLC (NASDAQ:LIVN) Shares Bought by BNP Paribas Financial Markets - Defense World
Combined Companies Sorin and Cyberonics Will Be Renamed LivaNova - Medical Product Outsourcing
LivaNova to Present at the Jefferies Global Healthcare Conference - The Joplin Globe
LIVN Stock Rating Reiterated at 'Buy' by Needham Analyst | LIVN - GuruFocus
LivaNova PLC (NASDAQ:LIVN) Q1 2025 Earnings Call Transcript - Insider Monkey
How to Take Advantage of moves in (LIVN) - news.stocktradersdaily.com
LivaNova PLC: Strong Growth Amidst Challenges in Earnings Call - TipRanks
Livanova Plc (LIVN) 財務データ
収益
当期純利益
現金流量
EPS
Livanova Plc (LIVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Makatsaria Vladimir | Chief Executive Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
9,330 |
0 |
9,330 |
| KOZY WILLIAM A | Director |
Mar 30 '25 |
Option Exercise |
0.00 |
1,034 |
0 |
28,496 |
| Hutchinson Michael Damon | Chief Legal Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
2,930 |
0 |
6,686 |
| Shvartsburg Alex | Chief Financial Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
11,083 |
0 |
30,196 |
| Poletti Franco | President, Cardiopulmonary |
Mar 30 '25 |
Option Exercise |
0.00 |
1,257 |
0 |
8,475 |
| Hutchinson Michael Damon | Chief Legal Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
2,254 |
0 |
4,540 |
| Poletti Franco | President, Cardiopulmonary |
Dec 15 '24 |
Option Exercise |
0.00 |
967 |
0 |
7,634 |
| Barry James Christopher | Director |
Dec 15 '24 |
Option Exercise |
0.00 |
1,709 |
0 |
1,709 |
| Shvartsburg Alex | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
613 |
0 |
19,342 |
| Bianchi Francesco | Director |
Dec 11 '24 |
Sale |
50.99 |
1,250 |
63,738 |
7,522 |
0.56%
1.70%
大文字化:
|
ボリューム (24 時間):